Table 3.

Studies describing inpatient care with length of stay associated with Pneumocystis jirovecii pneumonia.

Author	Year	Study design	Study period	Country	Level of care	Population description	No. of patients	No. of days in hospital
Báez-Saldaña et al.	2015	RCS SC	January 2010–December 2011	Mexico	Tertiary	Adult patients with HIV-AIDS diagnosed with infectious respiratory disease	Total: 308 Patients with PJP: 142 (46.1%)	13 (IQR: 10–23)
Creemers-Schild et al.	2016	RCS SC	January 2003–July 2013	Netherlands	Tertiary	Adult patients diagnosed with PJP and treated with TMP–SMX	104	Low-dose TMP–SMX: 15 (IQR: 9–24) Intermediate-dose TMP–SMX: 15 (IQR: 8–33)
Lee et al.	2020	RCS SC	January 1997–March 2019	South Korea	Tertiary	Kidney transplant recipients diagnosed with PJP	Total: 1994 Patients with PJP only: 38 (1.9%) Patients with PJP + CMV: 14 (0.7%)	PJP only: 19 (SD: 14.7) PJP plus CMV: 29.7 (SD: 10.8)
Rego de Figueiredo et al.	2019	RCS SC	2011–2016	Portugal	Tertiary	Adult patients diagnosed with PJP	Total: 129 HIV-AIDS: 75 (58.1%) HIV-negative: 54 (41.9%)	Total: 28.3 (SD: 20.8) HIV-AIDS: 27.8 (SD: 22.6) HIV-negative: 29.1 (SD: 18.2)
Shi et al.	2020	RCS SC	January 2014–December 2018	China	Tertiary	Adults with SRD admitted to the ICU due to acute respiratory failure	Total: 259 Confirmed PJP: 103 (39.8%)	22 (IQR: 8–37)
Singh et al.	2019	RCS SC	March 2014–March 2017	India	Tertiary	Patients with HIV-AIDS who developed laboratory-confirmed PJP	PJP diagnosed: 76 Both PCR and microscopic confirmation of PJP: 17 (22.4%)	<4 weeks n = 12/12 (100.0%)

CMV, cytomegalovirus; ICU, intensive care unit; IQR, interquartile range; MC, multicentre; PCR, polymerase chain reaction; PJP, Pneumocystis jirovecii pneumonia; RCS, retrospective cohort study; SC, single centre; SRD, systemic rheumatic disease; TMP–SMX, trimethoprim–sulfamethoxazole.

Data reported as it appears in the source papers. Numbers of days in hospital reported as median (IQR) or mean (SD) as per source.